About BioXell
BioXell is a company based in Segrate (Italy) founded in 2002 was acquired by Cosmo Pharmaceuticals in November 2009. BioXell has raised $79.28 million across 5 funding rounds from investors including Cosmo Pharmaceuticals, Life Sciences Partners and BB Biotech. BioXell operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Segrate, Italy
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$79.28 M (USD)
in 5 rounds
-
Latest Funding Round
$12.57 M (USD), Series C
Mar 15, 2006
-
Investors
Cosmo Pharmaceuticals
& 8 more
-
Employee Count
Not available
-
Acquired by
Cosmo Pharmaceuticals
(Nov 18, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of BioXell
BioXell has successfully raised a total of $79.28M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $12.57 million completed in March 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioXell
BioXell has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Cosmo Pharmaceuticals, Life Sciences Partners and BB Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Locked | Locked | Locked | |
|
Venture capital investments in technology startups and entrepreneurs.
|
Locked | Locked | Locked | |
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked |
Investor details for BioXell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioXell
Investment portfolio details for BioXell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioXell
Detailed financials for BioXell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioxell Comparisons
Peer comparison for BioXell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioXell
BioXell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for allergic and inflammatory diseases are developed.
|
Detailed competitors of BioXell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioxell
Complete news archive for BioXell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioXell
BioXell was founded in 2002.
BioXell is headquartered in Segrate, Italy. It is registered at Segrate, Lombardy, Italy.
BioXell is a funded company, having raised a total of $79.28M across 5 funding rounds to date.
BioXell was an Italian, clinical stage biopharma developing small molecule and antibody therapeutics for chronic inflammatory and autoimmune diseases. The company was founded with 22M funding as a spinout of Roche Milano Ricerche, a leading biomedical research institute. BioXell worked on urology, inflammation, pain, and other related disorders. The company was focusing on the development of monoclonal antibody BXL1H5 for the treatment of chronic pain- This was later licensed to Novo Nordisk. Its lead compound, Elocalcitol, a VD3 analog, has completed a Phase IIb clinical trial in benign prostatic hyperplasia and a Phase IIb clinical trial in overactive bladder. The company is also developing BXL746, a vitamin D analog under Phase I clinical trail, for the prevention of post-surgical adhesion formation. BioXell had a license and collaboration agreement with Merck for the development of therapeutic and diagnostic products related to triggering receptors expressed on myeloid cells. The company was acquired by Cosmo Pharma in Nov 2009 for 41M.
BioXell's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
BioXell has 9 investors. Key investors include Cosmo Pharmaceuticals, Life Sciences Partners, BB Biotech, Index Ventures, and TVM Capital Life Science.